Pavlides, MichaelMichaelPavlidesMózes, Ferenc EFerenc EMózesAkhtar, SalmaSalmaAkhtarWonders, KristyKristyWondersCobbold, JeremyJeremyCobboldTunnicliffe, Elizabeth MElizabeth MTunnicliffeAllison, MichaelMichaelAllisonGodfrey, Edmund MEdmund MGodfreyAithal, Guruprasad PGuruprasad PAithalFrancis, SusanSusanFrancisRomero-Gomez, ManuelManuelRomero-GomezCastell, JavierJavierCastellFernandez-Lizaranzu, IsabelIsabelFernandez-LizaranzuAller, RocioRocioAllerGonzález, Rebeca SigüenzaRebeca SigüenzaGonzálezAgustin, SalvadorSalvadorAgustinPericàs, Juan MJuan MPericàsBoursier, JeromeJeromeBoursierAube, ChristopheChristopheAubeRatziu, VladVladRatziuWagner, MathildeMathildeWagnerPetta, SalvatoreSalvatorePettaAntonucci, MichelaMichelaAntonucciBugianesi, ElisabettaElisabettaBugianesiFaletti, RiccardoRiccardoFalettiMiele, LucaLucaMieleGeier, AndreasAndreasGeierSchattenberg, Jörn MJörn MSchattenbergTilman, EmrichEmrichTilmanEkstedt, MattiasMattiasEkstedtLundberg, PeterPeterLundbergBerzigotti, AnnalisaAnnalisaBerzigotti0000-0003-4562-9016Huber, Adrian ThomasAdrian ThomasHuberPapatheodoridis, GeorgeGeorgePapatheodoridisYki-Järvinen, HanneleHanneleYki-JärvinenPorthan, KimmoKimmoPorthanSchneider, Moritz JörgMoritz JörgSchneiderHockings, PaulPaulHockingsShumbayawonda, ElizabethElizabethShumbayawondaBanerjee, RajarshiRajarshiBanerjeePepin, KayKayPepinKalutkiewicz, MikeMikeKalutkiewiczEhman, Richard LRichard LEhmanTrylesinksi, AldoAldoTrylesinksiCoxson, Harvey OHarvey OCoxsonMartic, MiljenMiljenMarticYunis, CarlaCarlaYunisTuthill, TheresaTheresaTuthillBossuyt, Patrick MPatrick MBossuytAnstee, Quentin MQuentin MAnsteeNeubauer, StefanStefanNeubauerHarrison, StephenStephenHarrison2024-10-252024-10-252023-11https://boris-portal.unibe.ch/handle/20.500.12422/170504Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of the metabolic syndrome with global prevalence reaching epidemic levels. Despite the high disease burden in the population only a small proportion of those with NAFLD will develop progressive liver disease, for which there is currently no approved pharmacotherapy. Identifying those who are at risk of progressive NAFLD currently requires a liver biopsy which is problematic. Firstly, liver biopsy is invasive and therefore not appropriate for use in a condition like NAFLD that affects a large proportion of the population. Secondly, biopsy is limited by sampling and observer dependent variability which can lead to misclassification of disease severity. Non-invasive biomarkers are therefore needed to replace liver biopsy in the assessment of NAFLD. Our study addresses this unmet need. The LITMUS Imaging Study is a prospectively recruited multi-centre cohort study evaluating magnetic resonance imaging and elastography, and ultrasound elastography against liver histology as the reference standard. Imaging biomarkers and biopsy are acquired within a 100-day window. The study employs standardised processes for imaging data collection and analysis as well as a real time central monitoring and quality control process for all the data submitted for analysis. It is anticipated that the high-quality data generated from this study will underpin changes in clinical practice for the benefit of people with NAFLD. Study Registration: clinicaltrials.gov: NCT05479721.en2D shear wave elastography 2DSWE DeMILI Diffusion weighted imaging Fibro-MRI Iron corrected T1 Liver Multiscan Magnetic resonance elastography NASH NASH-MRI PDFF Proton density fat fraction R2* T1 mapping T2* liver stiffness pSWE point shear wave elastography ultrasound elastography vibration controlled transient elastography600 - Technology::610 - Medicine & healtharticle10.48350/1869693780222110.1016/j.cct.2023.107352